929016-96-6

Pracinostat (SB939) is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in Clinicalal trials, allowing oral dosing. Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.

Pracinostat dihydrochloride is a highly effective histone deacetylase (HDAC) inhibitor with IC₅₀ values ranging from 40 to 140 nM, utilized in cancer research. Additionally, it inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC₅₀ of less than 10 nM.